Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AVDL vs PAHC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PAHC Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)

PAHC Overall Winner 6-Pillar Tally: AVDL 1 – 5 PAHC Matrix Metrics: AVDL 4 – 6 PAHC

As of Nov 20, 2026, Phibro Animal Health Corporation Class A (PAHC) is the stronger overall head-to-head candidate over Avadel Pharmaceuticals plc Ordinary Share (AVDL) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). AVDL carries a Unified Composite Score of 62.9/100 (BUY) at $21.64 (28.8x Forward P/E, 2.5% operating margin), whereas PAHC carries 65.9/100 (BUY) at $33.29 (10.0x Forward P/E, 12.7% operating margin).

  • Growth vs. Quality Trade-Off: PAHC earns the overall head-to-head edge with a stronger Unified Composite Score (65.9/100 BUY vs. AVDL 62.9/100 BUY) and 1.04β · 55% Vol risk profile, whereas AVDL leads top-line expansion (+54.9% YoY revenue growth, 0.07x PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: AVDL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3); meanwhile PAHC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AVDL vs PAHC
AVDL NASDAQ
Avadel Pharmaceuticals plc Ordinary Share
Pharmaceutical Preparations
$21.64
+0.05% 1D
Market Cap $2.1B
TTM Revenue $249M
Forward P/E 28.8x
Beta / 30D Vol 0.14β · 2% Vol
Unified Composite Score
62.9 / 100 BUY
Tech 75.0 Fund 60.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 62
RSI-14: 62.3 · SMA20: $21.56 · SMA50: $21.50
PAHC NASDAQ Head-to-Head Winner
Phibro Animal Health Corporation Class A
Pharmaceutical Preparations
$33.29
-2.32% 1D
Market Cap $1.4B
TTM Revenue $1.54B
Forward P/E 10.0x
Beta / 30D Vol 1.04β · 55% Vol
Unified Composite Score
65.9 / 100 BUY
Tech 70.0 Fund 65.0 Flow 65.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -0.3%), weak momentum, RSI 38
RSI-14: 37.7 · SMA20: $36.30 · SMA50: $36.51

6-Pillar Scorecard Institutional Category Breakdown (AVDL 1 – 5 PAHC)

Columns: Metric · AVDL · PAHC
1. Valuation Multiples PAHC
Forward P/E 28.8x 10.0x
Trailing P/E 16.8x 14.2x
PEG Ratio 0.07x 1.68x
EV / Revenue 8.5x 1.4x
2. Growth & Scale AVDL
Revenue Growth (YoY) +54.9% +6.3%
Earnings Growth (YoY) +0.0% +10.8%
TTM Revenue (USD) $249M $1.54B
Market Cap $2.1B $1.4B
3. Profitability & Quality PAHC
Gross Margin 94.9% 33.3%
Operating Margin 2.5% 12.7%
Net Profit Margin -0.1% 6.7%
Return on Equity (ROE) -0.3% 28.2%
4. Balance Sheet & Cash Flow PAHC
Cash Generation (TTM) $2.7M EBITDA $22M
Cash Flow Margin 1.1% EBITDA Mgn 1.4%
Net Cash / Leverage $1.01 Book/Sh · -0.3% ROE $714M Net Debt (1.89x D/E)
Dividend Yield None (0.00%) 1.35%
5. Options & Positioning PAHC
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 2.4% (<1st %ile) 70.3% (9th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup ACCUMULATION · Markdown
6. R&D & Supply-Chain Moat PAHC
OpEx & R&D Intensity N/A 20.6% of Rev ($317M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AVDL (4) vs PAHC (6)
Institutional Metric AVDL PAHC Criterion Row Edge
Market Capitalization
Scale
$2.1B $1.4B Larger Scale AVDL
Trailing P/E Ratio
Valuation
16.8x 14.2x Lower Multiple PAHC
Forward P/E Ratio
Valuation
28.8x 10.0x Lower Multiple PAHC
Revenue Growth (YoY)
Growth
+54.9% +6.3% Higher Growth AVDL
Operating Margin (TTM)
Profitability
2.5% 12.7% Higher Margin PAHC
Net Profit Margin
Profitability
-0.1% 6.7% Higher Margin PAHC
Return on Equity (ROE)
Capital Efficiency
-0.3% 28.2% Higher ROE PAHC
52-Week Range Position
Momentum
89% ($6–$24) 16% ($28–$60) Stronger Trend AVDL
Beta / 30D Volatility
Risk Regime
0.14β · 2% Vol 1.04β · 55% Vol Lower Realized Risk AVDL
Unified Institutional Score
Composite Signal
62.9 / 100 (BUY) 65.9 / 100 (BUY) Higher Composite PAHC
Trailing 12M Revenue (USD)
Operating Scale
$249M $1.54B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
94.9% 33.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.07x PEG · 8.5x EV/Rev 1.68x PEG · 1.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$2.7M EBITDA ($1.01 Book/Sh · -0.3% ROE) $22M ($714M Net Debt (1.89x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PAHC +28.7 pp
AVDL: +0.65% · PAHC: +29.35%
3M Horizon PAHC +30.82 pp
AVDL: -6.32% · PAHC: +24.5%
6M Horizon PAHC +30.82 pp
AVDL: -6.32% · PAHC: +24.5%
1Y Horizon PAHC +30.82 pp
AVDL: -6.32% · PAHC: +24.5%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AVDL vs PAHC. Trailing 12-month operating profitability (AVDL 2.5% vs PAHC 12.7%) and valuation multiples (AVDL 28.8x vs PAHC 10.0x Forward P/E) are benchmarked directly in Pillar 4 below.

AVDL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$249M
Gross Margin94.9%
Op. Margin2.5%
ROE / Fwd P/E-0.3% · 28.8x
PAHC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.54B
Gross Margin33.3%
Op. Margin12.7%
ROE / Fwd P/E28.2% · 10.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AVDL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 2.4%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AVDL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PAHC CONSOLIDATION
56d in phase · OBV ACCUMULATION
Current IV 70.3%
IV Percentile 9th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact PAHC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AVDL Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.1B market capitalization and 2.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PAHC Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $1.4B market capitalization and 12.7% operating margin.
OpEx & R&D Reinvestment 20.6% of Rev ($317M)
90D Engineering Disclosures 0 Published

Investor FAQ AVDL vs PAHC Key Questions & Quantitative Answers

As of Nov 20, 2026, Phibro Animal Health Corporation Class A (PAHC) is the stronger overall head-to-head candidate over Avadel Pharmaceuticals plc Ordinary Share (AVDL) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). AVDL carries a Unified Composite Score of 62.9/100 (BUY) at $21.64 (28.8x Forward P/E, 2.5% operating margin), whereas PAHC carries 65.9/100 (BUY) at $33.29 (10.0x Forward P/E, 12.7% operating margin). Growth vs. Quality Trade-Off: PAHC earns the overall head-to-head edge with a stronger Unified Composite Score (65.9/100 BUY vs. AVDL 62.9/100 BUY) and 1.04β · 55% Vol risk profile, whereas AVDL leads top-line expansion (+54.9% YoY revenue growth, 0.07x PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: AVDL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3); meanwhile PAHC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AVDL leads the Growth & Scale pillar: AVDL posts +54.9% YoY revenue growth and +0.0% YoY earnings growth on $249M TTM revenue (94.9% gross margin, 2.5% operating margin), compared with PAHC at +6.3% YoY revenue growth and +10.8% YoY earnings growth on $1.54B TTM revenue (33.3% gross margin, 12.7% operating margin). On trailing 12-month operating scale, AVDL generates $249M in USD-normalized revenue versus $1.54B for PAHC. In operating R&D and SG&A reinvestment, AVDL deploys N/A (0 90-day corporate R&D disclosures) versus 20.6% of Rev ($317M) (0 disclosures) for PAHC.

PAHC screens cheaper on headline valuation multiples. AVDL trades at 28.8x Forward P/E, 16.8x Trailing P/E, 0.07x PEG, and 8.5x EV/Revenue (1.1% EBITDA margin), whereas PAHC trades at 10.0x Forward P/E, 14.2x Trailing P/E, 1.68x PEG, and 1.4x EV/Revenue (1.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AVDL (-0.3% ROE) versus PAHC (28.2% ROE) capital efficiency.

In options market volatility and institutional positioning, AVDL carries 2.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 2% Vol realized risk). By comparison, PAHC carries 70.3% implied volatility (9th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.04β · 55% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.